|  |  |
| --- | --- |
| AMFEP/2012/02(references) | 31JAN2012 |

**Re. Enzyme and classification of enzyme products in accordance with the CLP regulation**

**References**

1) ECHA, “Guidance for identification and naming of substances under REACH“, 2007, section 4.3.2.3. , http://echa.europa.eu/web/guest/guidance-documents/guidance-on-the-different-methods-under-reach

2) HERA risk assessment on Protease, <http://www.heraproject.com/RiskAssessment.cfm?SUBID=22>, and HERA risk assessment on Amylase/Lipase/Cellulase, <http://www.heraproject.com/RiskAssessment.cfm?SUBID=38>.

3) Basketter D.A. et al.: Defining occupational and consumer exposure limits for enzyme protein respiratory allergens under REACH. Toxicology. 268:165-170, 2010.



4) Basketter D.A. et al.: Enzymes, detergents and skin: facts and fantasies. Br. J. Dermatol. 158, 1177-1181, 2008.



5) AMFEP (the Association of Manufacturers and Formulators of Enzyme Products) policy on classification of enzymes as “Respiratory Sensitisation Category 1” in accordance with the EU Regulation on classification, labelling and packaging of substances and mixtures (EC No 1272/2008, “CLP Regulation”) (Amfep/09/73)



6) Manufacturers and importers of enzymes have created an open consortium, The Enzymes REACH Consortium (“ERC”) with the overall purpose of facilitating a smooth REACH implementation: [www.enzymes-reach.org](http://www.enzymes-reach.org).

7) The Enzymes REACH Consortium document. Safety evaluation of technical enzyme products with regards to the REACH legislation (ERpC/09/06)



8) Valenta, R., and D. Kraft. 2002. From allergen structure to new forms of allergen specific immunotherapy. Curr. Opin. Immunol. 14: 718–727.

9) Valenta, R. 2002. The future of antigen-specific immunotherapy of allergy. Nat. Rev. Immunol. 2: 446–453.

10) Takai, T., et al. 1997. Engineering of the major house dust mite allergen Der f2 for allergen-specific immunotherapy. Nat. Biotechnol. 15: 754–758.

11) Takai, T., et al. 2000. Unlocking the allergenic structure of the major house dust mite allergen Der f 2 by elimination of key intramolecular interactions. FEBS Lett. 484: 102–107.

12) Nakazawa, T., et al. 2005. Multiple-mutation at a potential ligand-binding region decreased allergenicity of a mite allergen Der f 2 without disrupting global structure. FEBS Lett. 579: 1988–1994.

13) Kikuchi Y. , et al. 2006. Crucial commitment of proteolytic activity of a purified recombinant major house dust mite allergen Der p 1 to sensitization towards IgE and IgG responses. J Immunol 177:1609-1617.

14) Høst A,. and Halken S. 2004. Hypoallergenic formulas--when, to whom and how long: after more than 15 years we know the right indication!. Allergy 59 Suppl 78:45-52.

15) The Enzymes REACH Consortium document. Calculation of Tonnage for Enzyme Substances (ERpC/09/05)

